logo
Plus   Neg
Share
Email

Aviva Appoints Amanda Blanc To Succeed Maurice Tulloch As CEO, With Immediate Effect

Aviva plc (AV.L,AV) announced Monday the appointment of Amanda Blanc as Chief Executive Officer with immediate effect. She succeeds Maurice Tulloch, the previous Chief Executive, who has stepped down from the role and retired from his position on the Board citing family health reasons.

Blanc is currently an Independent Non-Executive Director at the company. She was appointed to the Aviva Board in January 2020 and chairs the Customer, Conduct and Reputation Board Committee.

Following her appointment, Blanc will step down from all of her current Non-Executive commitments. She will continue in her voluntary role as Chair of the Welsh Professional Rugby Board.

Previously, she was CEO, EMEA & Global Banking Partnerships at Zurich Insurance Group. Prior to that, she was Group CEO, AXA UK, PPP and Ireland and has served as Chair of the Association of British Insurers and President of the Chartered Insurance Institute.

Maurice joined Aviva in 1992, and joined the Aviva Board in 2017. He was appointed as Chief Executive in March 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT